Gene therapy may yield marked improvement in ED
Injection of a gene therapy vector in rats with erectile dysfunction enabled the return of normal function within 4 weeks, according to a study from the University of Pittsburgh School of Medicine. The research may be the first step in developing a new mode of long-term ED treatment, researchers say.
Injection of a gene therapy vector in rats with erectile dysfunction enabled the return of normal function within 4 weeks, according to a study from the University of Pittsburgh School of Medicine. The research may be the first step in developing a new mode of long-term ED treatment, researchers say.
Researchers injected the gene for the glial cell line-derived neurotrophic factor (GDNF) or the GDNF family ligand (neurturin) into a genetically engineered herpes simplex virus (HSV). Then either recombinant virus was injected into the damaged cavernous nerve of rats. Controls received the unaltered virus.
Four weeks after treatment, rats given HSV-GDNF experienced improved recovery of intracavernous pressure (ICP) and systemic arterial pressure (AP) compared with both controls and untreated mice with ED, lead author Joseph C. Glorioso, III, PhD, reported at the American Society of Gene Therapy annual meeting in Seattle. Rats treated with HSV-neurturin also had marked recovery compared with controls or untreated mice.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
